Some board positions last a few years. Others span decades. Reeve Waud has served on the Acadia Healthcare board since December 2005—20 years of continuous service at a single company.
This extended tenure is notable in private equity, where firms typically exit investments within five to seven years. Yet Reeve Waud continues as Founder and Chairman even as Acadia operates as a publicly traded company with market capitalization in the billions.
Founding Role Dating to December 2005
Acadia Healthcare began as a Waud Capital Partners platform investment. Reeve Waud and his team identified behavioral healthcare as an attractive consolidation opportunity. The sector was fragmented, with many facilities operating independently or as small regional chains.
Acadia Healthcare Company, LLC was formed in December 2005, and Reeve Waud has served as a director since that time. The company initially focused on acquiring and operating psychiatric hospitals and substance abuse treatment centers.
From 2005 through 2011, Acadia expanded through acquisitions. The company purchased existing facilities, implemented operational improvements, and integrated them into a growing network. Some acquisitions added single facilities; others brought multiple locations.
Capital for these acquisitions came initially from Waud Capital Partners. As the platform grew, Acadia accessed debt financing to supplement equity. This combination of equity and leverage is typical for healthcare services consolidations.
Independent Chairman Responsibilities
Acadia completed its initial public offering in November 2011. The IPO transitioned the company from a private portfolio investment to a publicly traded entity with responsibilities to public shareholders.
Following the IPO, Reeve Waud’s role evolved. He became an independent chairman—meaning he does not serve in management but provides board oversight. Independent directors are meant to represent shareholder interests rather than management interests.
Board responsibilities include reviewing company performance, approving major transactions, evaluating executive compensation, and ensuring regulatory compliance. For a healthcare company, board oversight also extends to clinical quality, patient safety, and accreditation maintenance.
Reeve Waud’s institutional knowledge, spanning Acadia’s 20-year history, provides context for strategic decisions. He understands which acquisitions succeeded, which faced integration challenges, and which markets proved more difficult than expected.
Overseeing 260 Facilities and 11,400 Beds
As of 2025, Acadia Healthcare operates 260 facilities across 40 states and Puerto Rico. These facilities include acute care psychiatric hospitals, residential treatment centers, outpatient clinics, and comprehensive treatment centers.
The company maintains approximately 11,400 beds across its network. Patient populations include individuals requiring treatment for psychiatric conditions, substance use disorders, and eating disorders. Services range from short-term crisis stabilization to longer-term residential treatment.
Acadia’s revenue comes from multiple payor sources: approximately 57% Medicaid, 26% commercial insurance, 14% Medicare, and 3% self-pay and other sources (based on project documents). This payor mix reflects the patient populations served and the types of facilities operated.
Reeve Waud’s continued board service, two decades after founding the company, is uncommon. Most private equity-backed companies transition their boards post-exit, replacing investor directors with independent directors who lack affiliation with previous owners. That Acadia has maintained its founder as chairman suggests the board values his expertise and institutional knowledge.Waud Capital Partners, founded by Reeve Waud in 1993, manages approximately $4.6 billion in assets across healthcare and software investments. The firm has completed more than 460 investments since founding.